TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES.

Zhu M.; Smith E.; Kirshner J.; Toroghi M.; Davis J.; Di-Cioccio A.; Retter M.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES.

【24h】

TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES.

机译：Regn1979的翻译结果，一种人抗CD20 X抗CD3双特异性抗体：从CD20 + B细胞恶性肿瘤患者临床前进的第一中研究。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2020年第s1期|共1页
作者
Zhu M.; Smith E.; Kirshner J.; Toroghi M.; Davis J.; Di-Cioccio A.; Retter M.;
展开▼
作者单位

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES. [J] . Zhu M., Smith E., Kirshner J., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：Regn1979的翻译结果，一种人抗CD20 X抗CD3双特异性抗体：从CD20 + B细胞恶性肿瘤患者临床前进的第一中研究。
2. PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA. [J] . Yang F., Zhu M., Toroghi M., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：患有非霍奇金淋巴瘤患者的药代动力学和REGN1979的曝光响应，是非霍奇金淋巴瘤患者的抗CD20 x抗CD3抗体。
3. Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes [J] . Bannerji Rajat, Arnason Jon E., Advani Ranjana, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：RegN1979的临床活性，抗CD20 x抗CD3双特异性抗体，复发/难治滤泡淋巴瘤（FL），弥漫性大B细胞淋巴瘤（DLBCL）和其他B细胞非霍奇金淋巴瘤（B. -NHL）亚型
4. Novel Anti-CD20 Antibody: Development, Characterization and Preclinical Studies [C] . Alexey Misorin, Iakov Ustiugov, Sergey Diduk, Protein Engineering Summit. . 2018

机译：新型抗CD20抗体：发展，表征和临床前研究
5. Immunotherapy with FBTA05 (Bi20) a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven open-label non-randomized uncontrolled dose-escalating Phase I/II-trial [O] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案非随机不受控制剂量递增的I / II试验阶段
6. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [O] . 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段

TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES.

著录项

相似文献

相关主题

期刊订阅